Revalia Bio

Revalia Bio reimagines how we treat chronic diseases that end in organ failure. Revalia disrupts the current preclinical model for device and drug development by using human organs obtained from deceased donors. Their proprietary data capture, integration and analysis systems allows Revalia to record up to five days of data (e.g., expression, metabolic, and functional) from an organ in response to the presence or absence of interventions, and create dynamic digital maps (“Digital Twins”) of organs. This technology has the potential to transform organ donation and be a catalyst for breakthrough therapies and diagnostics.